Business Context and Reporting Period
Aclaris Therapeutics, Inc. (ACRS) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small and large molecule product candidates for immuno-inflammatory diseases. The company utilizes its proprietary KINect drug discovery platform and an integrated approach to small and large molecules. This Form 10-K covers the fiscal year ended December 31, 2025.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $7.8 million | $18.7 million |
| Net Loss | $(64.9) million | $(132.1) million |
| Research & Development Expenses | $52.6 million | $33.6 million |
| Cash, Cash Equivalents, and Marketable Securities | $151.4 million | $203.9 million |
| Accumulated Deficit | $(967.8) million | $(902.9) million |
Revenue Breakdown (2025): Licensing revenue was $6.0 million, and Contract Research revenue was $1.9 million. The company recognized $3.8 million in non-cash royalty income from the sale of future royalties to OMERS.
Liquidity: As of December 31, 2025, the company held $151.4 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations for more than 12 months.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by $10.9 million (58%) compared to 2024. This was primarily due to the absence of large milestone payments from Sun Pharma and Eli Lilly that were recognized in 2024.
- Net Loss Improvement: Net loss decreased by $67.1 million (51%) year-over-year. This improvement was driven by a significant reduction in total costs and expenses, specifically the absence of $86.9 million in In-Process Research and Development (IPR&D) expenses recorded in 2024 related to the acquisition of bosakitug and ATI-052.
- R&D Expense Increase: Research and development expenses increased by $19.1 million (57%) to $52.6 million. This increase was driven by the full-year impact of the newly acquired assets (bosakitug and ATI-052) and increased clinical development activities for ATI-2138 and ATI-9494.
- Acquisition Activity: In November 2024, the company entered into an exclusive license agreement with Biosion, Inc. for bosakitug and ATI-052, paying $30.0 million in upfront cash and issuing warrants. This transaction resulted in significant IPR&D charges in 2024, which were not repeated in 2025.
Guidance, Outlook, and Risks
Clinical Pipeline Progress:
- Bosakitug (ATI-045): A Phase 2 trial in atopic dermatitis was initiated in June 2025. Top-line data is expected in the second half of 2026.
- ATI-2138: Positive top-line results from a Phase 2a trial in atopic dermatitis were announced in July 2025, meeting primary and key secondary endpoints.
- ATI-052: Positive interim results from a Phase 1a/1b study in healthy volunteers were announced in January 2026. Phase 1b proof-of-concept trials in atopic dermatitis and asthma were initiated in early 2026, with data expected in the second half of 2026.
- ATI-9494: An Investigational New Drug (IND) application is expected to be filed in the second half of 2026.
Outlook: The company expects to continue to incur significant expenses and operating losses as it advances its product candidates. It anticipates needing substantial additional funding to meet financial obligations and pursue business objectives.
Key Risks:
- Capital Requirements: The company has a history of significant losses and will require additional capital. Failure to raise funds could force curtailment of operations.
- Regulatory and Clinical Risk: Success depends on the successful completion of clinical trials and regulatory approvals, which are uncertain.
- Third-Party Dependence: The company relies on third parties for manufacturing (including WuXi Biologics in China) and clinical trials. The BIOSECURE Act poses potential risks to supply chains involving Chinese manufacturers.
- Partnership Strategy: Future revenue is heavily dependent on identifying and consummating transactions with third-party partners for development and commercialization.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $151.4 million cash balance against the projected burn rate, given the increased R&D spend and lack of near-term product revenue.
- Partnership Status: Monitor progress in securing third-party partners for bosakitug and ATI-052, as the company intends to partner for further development and commercialization rather than self-fund commercialization.
- Manufacturing Risks: Assess the potential impact of the BIOSECURE Act on the company's reliance on WuXi Biologics for manufacturing clinical supplies.
- Clinical Data Readouts: Track the timing and results of the Phase 2 bosakitug data (H2 2026) and Phase 1b ATI-052 data (H2 2026), which are critical value inflection points.
- Contingent Consideration: Review the $11.0 million contingent consideration liability related to the Confluence acquisition and the assumptions used to value it.